Reaxys® Medicinal Chemistry Provided as Part of Elsevier's Suite of Life Science Solutions Delivers High Quality Content to Improve Drug Discovery and Development PR Newswire AMSTERDAM, February 4, 2013 AMSTERDAM, February 4, 2013 /PRNewswire/ -- Comprehensive, referenced and well-structured data allows users to increase speed and accuracy of decision making in the drug development process Elsevier , a world-leading provider of scientific, technical and medical information products and services, today announced the launch of Reaxys Medicinal Chemistry. It offers medicinal chemists access to comprehensive, referenced and well-structured data to enhance the compound selection process across discovery and pre-clinical stages in drug research and development. Reaxys Medicinal Chemistry will significantly improve the efficiency and productivity of researchers engaged in the process of designing compounds and optimizing their compatibility with one or more targets in order to successfully treat a disease. Dr. Juergen Swienty-Busch, Product Lead for the Reaxys suite at Elsevier, said, "The greatest challenge of medicinal chemistry is to reduce the number of drug candidates that fail in late stages, significantly increasing the cost of bringing a drug to market. The well-known mantra 'fail early, fail cheap' is now central to the drug discovery process, with much of the responsibility borne by medicinal chemists." Medicinal chemists develop strategies to find new drugs and to improve not only the efficacy of compounds but also selectivity, ADME properties and safety end-points. To support these strategies, medicinal chemists need to have access to up-to-date, well organized and high-quality experimental data on druggable targets, pharmacological effects, biological data points, and ADME properties associated with chemical compounds. Reaxys Medicinal Chemistry sources its data from a vast repository of peer-reviewed journal articles, patents and regulatory information, encompassing millions of compounds and associated biological data linked to thousands of druggable proteins. It brings this information together into a single, easily searchable solution that gives pharmaceutical companies access to comparative data. Reaxys Medicinal Chemistry can be used in conjunction with Elsevier's suite of life science products; including Reaxys, the leading chemistry discovery engine, and PharmaPendium, which focuses on regulatory approvals and drug safety. This solution effectively brings together lead identification, confirmation and drug repurposing. About Reaxys® Reaxys® is a workflow solution for research chemists. Offering a wealth of experimentally validated information, Reaxys® combines reaction and substance data in organic, organometallic, inorganic and physical chemistry with synthesis planning. Researchers can get the information they need in a single overview, from source publications carefully selected for their importance and relevance to research chemists. Elsevier continues to engage with the chemistry community to ensure that Reaxys® continues to reflect how chemists think and work. For more information please visit https://www.reaxys.com/info/ . Reaxys and the Reaxys trademark are owned and protected by Reed Elsevier Properties SA and used under license. About Elsevier Elsevier is a world-leading provider of scientific, technical and medical information products and services. The company works in partnership with the global science and health communities to publish more than 2,000 journals, including The Lancet and Cell , and close to 20,000 book titles, including major reference works from Mosby and Saunders. Elsevier's online solutions include ScienceDirect , Scopus , Reaxys , ClinicalKey and Mosby's Nursing Suite , which enhance the productivity of science and health professionals, and the SciVal suite and MEDai's Pinpoint Review , which help research and health care institutions deliver better outcomes more cost-effectively. A global business headquartered in Amsterdam, Elsevier employs 7,000 people worldwide. The company is part of Reed Elsevier Group PLC , a world-leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange). Media contact Harald Boersma Director, Corporate Relations Elsevier +31-20-485-27-36 email@example.com
Reaxys® Medicinal Chemistry Provided as Part of Elsevier's Suite of Life Science Solutions Delivers High Quality Content to
Press spacebar to pause and continue. Press esc to stop.